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Abstract 
In this study, we investigated the affect and the role of growth factors on liver damage. 110 Sprague–Dawley rats 
were divided into 11 groups: a sham group, a control group, HGF, EGF, IGF, TGF groups of irreversible jaundiced rats 
and a control group and HGF, EGF, IGF, and TGF groups of reversible jaundiced rats (n = 10). In the irreversible jaun-
diced groups, the common bile duct was explorated, double ligated, and cut. 150 μg/kg/day HGF, 5 μg/kg/day EGF, 
5 μg/kg/day IGF, and 5 μg/kg/day TGF β-1 were injected intraperitoneally after the seventh post-operative day. In 
the reversible jaundiced group, the common bile duct was ligated and the ligation was resolved on the seventh 
post-operative day. For 5 days, growth factors were injected at the same dose. Ductal proliferation scores significantly 
decreased after growth factor administration in the EGF-A and TGF-A groups. Furthermore, ductal proliferation was 
decreased in the TGF-B group. As a result of this study, HGF was effective in the irreversible jaundiced groups and 
ineffective in the reversible jaundice groups. EGF was effective in the reversible jaundiced groups and ineffective in 
the irreversible jaundiced groups. In both the irreversible jaundiced and reversible jaundiced groups, IGF was ineffec-
tive, although TGF β-1 was effective. We believe that these results arise from the positive effects of effective doses of 
growth factor on liver damage.
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Background
Common bile duct stones, cholangiocellular carcinoma, 
pancreatic cancer, inflammation, trauma and other 
mechanical obstructions of the bile duct could result by 
obstructive jaundice. Due to obstruction of the bile duct 
jaundice occurs and follows by cholestatic liver damage. 
Furthermore, as a result of cholestatic liver damage, stel-
late cells activate and hepatocellular necrosis and bile 
duct epithelial proliferation occurs. As a result of jaun-
dice inflammation occurs in the liver tissue and due to 
the release of the inflammatory cytokines and free oxygen 
radicals liver injury starts. If the jaundice keeps on dur-
ing 48 h and more, early epithelial proliferation of biliary 
tract starts. Progression of epithelial proliferation contin-
ues during 5 days and makes a peak; after 5 days epithelial 
proliferation continues at a basal rate. Effects of obstruc-
tive jaundice on liver tissue can occur during the first 
7  days that can be called the acute period of cholestatic 
liver injury. The period of liver injury occurred longer than 
7 days called as chronic cholestatic period (Georgiev et al. 
2008). Cytotoxic biliary acids are responsible from the liver 
injury and fibrosis (Parola et  al. 1996). Jaundice could be 
presented in different clinical manifestation such as renal 
failure, coagulation disorders, malnutrition, sepsis, and an 
inability to heal wounds (Long et al. 2015; Li et al. 2015). 
Patients who admitted to the hospital because of obstruc-
tive jaundice are commonly treated by percutaneous exter-
nal biliary drainage or internal endoscopic biliary drainage 
as soon as after the diagnosis of severe obstructive jaun-
dice. Biliary drainage is more effective then medical treat-
ment. Endoscopic biliary drainage is more effective than 
percutaneous external drainage because of high rate of 
complications. Bleeding, hemobilia, bile leakage, biliary 
fistula and peritonitis may be listed among the complica-
tions of percutaneous biliary drainage (Pan et al. 2014).
Before surgical treatment surgeons must pay attention 
to protect patient from liver injury and during preopera-
tive period jaundice must be resolved. Posticteric injury 
occurs in liver tissue during the chronic cholestatic period 
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after the drainage of bile (Chen et al. 2015). Experimental 
CBD (common bile duct) ligation in rats is a reliable model 
represents the cholestatic liver disease in humans. By using 
the modifications of this experimental model, a newly 
reversible bile duct ligation model has been developed 
to investigate changes in posticteric liver damage (Oruc 
et  al. 2009). However; additional studies are required to 
determine the changes in liver tissue during the postict-
eric period and the factors affecting healing of cholestatic 
liver injury, and hepatocyte regeneration. In recent stud-
ies, positive effects of growth factors have been detected 
in liver regeneration. In particular, a mitogenic effect of 
hepatocyte growth factor (HGF) plays a protective role in 
necrotic and apoptotic impacts of bile acids on cholestatic 
livers. Although the expression of HGF results in increased 
CBDs in ligated rats; therapeutic effects of HGF are still 
being investigated (Xia et al. 2006). High serum HGF levels 
were reported in patients admitted to the hospital because 
of jaundice. Following external biliary drainage, the serum 
HGF level decreased (Higaki et  al. 1999). Epidermal 
Growth Factor (EGF) has protective effects against car-
bon tetrachloride-induced hepatic injury (Berlanga et  al. 
1998). Circulating and locally acting isoforms of insulin-
like growth factors protect cholangiocytes from cholestatic 
injury (Gatto et al. 2008). The protective and therapeutic 
effects of growth factors on cholestatic liver injuries dur-
ing the development and release of jaundice merits further 
investigations (Kedarisetty et  al. 2014). The aim of this 
study is to determine the role of growth factors in pro-
tecting the development of cholestatic liver injury and the 
positive effects on liver regeneration. In addition, we tried 
to define the effectiveness of growth factors on posticteric 
injury and anti-inflammatory events during the resolution 
of jaundice. It is sure that primary method to solve jaun-
dice is biliary drainage and growth factor may contribute 
to prevent hepatic damage.
Methods
Animals
All of the experimental studies were conducted in the 
laboratory of Eskisehir Osmangazi University’s Medical 
and Surgical Research Center with the approval of the 
Ethics and Research Committee of Eskisehir Osmangazi 
University. In this study, 110 Sprague–Dawley female and 
male rats weighing 230–260 g were used. The rats were 
kept at room temperature and in a light–dark cycle in 
individual plastic cages; there was free access to water 
and food for 7 days before the experimental procedure.
Experimental design and surgical procedure
The animals were divided into 11 groups, with at least 
10 rats in each group. After eight hours, the rats were 
administrated general anesthesia using 50 mg/kg sodium 
pentothal (Pental Sodium, İ.E, Ulagay, Turkey). The rats 
underwent a midline laparotomy incision by using an 
aseptic technique. In the sham group, the CBD was iso-
lated from the surrounding tissues by suspending the 
duodenum (without any additional procedures); the 
abdominal incision was closed using 3/0 silk sutures. 
Liver tissues and blood samples were taken on the 
7th day of the operation by a relaparotomy. An irrevers-
ible CBD ligation model was performed in the HGF A, 
EGF A, Insulin-like Growth Factor (IGF) A, Transform-
ing Growth Factor (TGF) A, and Control A groups. In the 
irreversible jaundice groups, the CBD proximal and distal 
segments were double ligated using 4/0 silk sutures. The 
CBD cut between the ligations. In the irreversible groups 
(HGF A, EGF A, IGF A, and TGF A), the rats under-
went a growth factor treatment 2 days after the surgical 
procedure during 5  days via intraperitoneal injection. 
We used 150 µgr/kg/day HGF (Catalog Number H1404, 
Sigma-Aldrich, Inc., Turkey), 150 µgr/kg/day EGF (Cata-
log Number E9644, Sigma-Aldrich, Inc. Turkey), 150 µgr/
kg/day IGF (Product Number I3769, Sigma-Aldrich, Inc. 
Turkey), and 150 µgr/kg/day TGF ß (TGF-b1 human, 
Catalog Number T7039, Sigma-Aldrich, Inc. Turkey). 
After treatment, liver tissue and blood samples was taken 
by relaparotomy.
A reversible CBD ligation model was used in the HGF 
B, EGF B, IGF B, TGF B, and Control B groups. The CBD 
was dissected gently from the surrounding tissues and a 
1–2 cm segment was released and prepared for ligation. 
A silicone tube clung around the prepared segment and a 
silicone band was double wrapped around the tube. The 
silicone band was tightened enough to stop the flow of 
bile right into the duodenum and a metal mini clip was 
placed below the silicone band. The goal of the procedure 
was to perform a procedure that would reliably and sim-
ply reverse jaundice without wounding the CBD and duo-
denum while releasing the ligation. On the 7th day of the 
operation, the CBD dissected, the adhesions divided into 
and the clip at the root of the band was gently removed. 
The silicone band was also taken out (Kirkland et al. 2010). 
All treatment groups in the reversible jaundice groups 
(HGF B, EGF B, IGF B, and TGF B) underwent growth 
factor treatments with the same dose as the irreversible 
groups for 5 days. At the end of the treatment liver, tissue 
and blood samples were taken by relaparotomy.
Biochemical analysis
Measurement of malondialdehyde (MDA) was made 
using the thiobarbituric acid method (Ohkawa et  al. 
1979). The total antioxidant capacity measured using a 
commercial Antioxidant Assay kit (Antioxidant Assay 
Kit, Catalog Number CS0790, Sigma-Aldrich, Inc.). 
Liver tissue samples were homogenized on cold ice and 
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buffered and then centrifuged at 12,000g for 15  min at 
4 °C. The supernatant was removed for study and placed 
on plates. The principle of the antioxidant assay relies on 
the formation of a ferryl myoglobin radical from met-
myoglobin and hydrogen peroxide. A soluble chromogen, 
green in color, can be determined spectrophotometri-
cally at 405  nm (Huang et  al. 2005). The blood samples 
were centrifuged at 5000g at 4  °C and the supernatants 
were removed. Serum Alanine aminotransferase (ALT), 
Aspartate Aminotransferase (AST), Alkaline phosphatase 
(ALP), Gamma-glutamyl transpeptidase (GGT), and total 
bilirubin and direct bilirubin levels were determined.
Pathological staining for liver injury
All tissues were fixed in 10 % neutral buffered formalin. 
Five-micron sections from the paraffin-embedded tissue 
were stained with hematoxylin and eosin and Masson’s 
Trichrome. Histopathological assessment was accom-
plished with a quantitative method. We used a scoring 
system for the ductal proliferation under 10× and 40× 
light microscopy (Olympus Bx40, Japan) (Sheen-Chen 
et al. 2006; Miyoshi et al. 1999).
Statical analysis
For the biochemical results, a one-way analysis of vari-
ance (one-way ANOVA) was applied. In this test, for 
multiple comparisons, the Turkey HDS method was used. 
For the histopathological scoring results, Mann–Whitney 
U test was used. Turkey HDS method and Kruskal–Wal-
lis test were used to determine differences between the 
groups.
Results
Biochemical analysis
In both control groups, serum biochemical parameters 
were used to determine the liver injury. The biochemical 
parameters of the reversible and irreversible groups were 
compared and the reversible groups showed significantly 
larger parameters (p  <  0.05). ALP levels were higher in 
the HGF A group (p  <  0.05). AST levels were higher in 
the TGF B group (p < 0.05). In the EGF B group, the total 
serum bilirubin level was higher than in the EGF A group 
and the direct bilirubin level was significantly lower in 
the EGF A group and higher in the HGF A and IGF A 
groups. In the irreversible jaundiced group, the total 
serum bilirubin levels were similar, excluding the EGF B 
group (p  <  0.05). Furthermore, there was no difference 
between all groups in GGT levels. Biochemical results 
were listed in Table 1.
Liver tissue antioxidant and MDA assay
The liver tissue MDA level was significantly higher in 
the irreversible jaundiced EGF A group than in the EGF 
B group. In the IGF B group, the MDA level was lower 
than in the IGF A group (p < 0.05). In the HGF and TGF 
treatment groups, MDA levels were similar for both the 
reversible and irreversible jaundiced groups (Fig. 1). Also, 
there was no significant difference among all groups in 
terms of liver tissue antioxidant assay levels (Fig. 2). Anti-
oxidant capacity and MDA levels of the liver tissue were 
listed in Table 2.
Histopathological evaluation
After H&E and Masson’s Trichrome staining, the liver 
tissues were evaluated and scored histological by the 
same pathologist, who was blinded to the experiment. 
The following sections were evaluated according to the 
modified histological activity index: portal inflamma-
tion, focal necrosis, confluent necrosis, piecemeal necro-
sis, apoptosis, and focal inflammation (Knodell et  al. 
1981; Ishak et al. 1995). Ductal proliferation was scored 
using the following grading system: 0 for <10 % of portal 
Table 1 Biochemical results of the all groups
ALT AST ALP Total bilirubin Direct bilirubin GGT
Sham 49.70 ± 6.00 149.80 ± 18.93 258.40 ± 23.82 0.09 ± 0.02 0.09 ± 0.15 7.70 ± 1.89
HGF A 148.60 ± 74.97 618.60 ± 376.55 880.30 ± 407.10 10.77 ± 2.19 8.80 ± 2.02 32.40 ± 6.70
EGF A 145.50 ± 65.36 697.60 ± 298.97 664.10 ± 237.57 9.07 ± 2.12 5.58 ± 2.57 39.10 ± 10.18
IGF A 220.90 ± 136.43 820.90 ± 621.50 856.00 ± 493.76 11.40 ± 1.74 8.63 ± 2.12 32.10 ± 4.93
TGF A 148.50 ± 61.91 478.90 ± 243.28 815.70 ± 267.67 11.53 ± 1.82 7.75 ± 1.98 31.60 ± 7.63
Control A 211.30 ± 80.81 622.80 ± 187.04 758.50 ± 192.11 10.90 ± 1.37 8.42 ± 1.25 32.10 ± 5.51
HGF B 731.50 ± 399.44 681.70 ± 226.30 505.90 ± 302.56 12.14 ± 1.70 9.17 ± 1.84 26.60 ± 5.04
EGF B 597.10 ± 361.76 711.50 ± 237.16 633.90 ± 247.38 12.46 ± 1.79 9.74 ± 1.54 38.10 ± 5.20
IGF B 568.70 ± 219.44 730.50 ± 185.72 677.90 ± 290.03 12.04 ± 0.97 9.21 ± 1.09 29.20 ± 4.37
TGF B 682.00 ± 199.50 973.30 ± 571.17 550.80 ± 316.82 10.79 ± 3.03 8.07 ± 2.86 31.70 ± 3.23
Control B 387.70 ± 294.53 826.60 ± 410.62 779.10 ± 283.79 11.02 ± 1.42 8.30 ± 1.39 31.10 ± 5.90
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areas involved, 1 for 10–50 % of portal areas involved, 2 
for >50  % of portal areas involved, 3 for a circumferen-
tial involvement of at least 50 % of the portal area with-
out a significant expansion of the portal tract, 4 for a 
circumferential involvement of at least 50 % of the portal 
area with significant expansion of the portal tract 5 for 
the same criterion as level 4, plus a bridging of the por-
tal tracts in <20  % of instances, and 6 for the same cri-
terion as level 4 plus >20 % of the portal tracts showing 
bridging involvement (Table 3) (Sheen-Chen et al. 2006). 
Histopathological score results were listed in Table  2. 
In the Control A group, the ductal proliferation score 
was significantly increased. Central necrosis, piecemeal 
necrosis, and focal necrosis areas were defined and the 
histopathological findings of cholestasis were determined 
in both control groups, particularly in Control B group. 
Ductal proliferation scores were significantly decreased 
in the EGF A and TGF A groups, while the IGF A group 
showed a decreased ductal proliferation score. The ductal 
proliferation score of the IGF B group was significantly 
higher while that in the TGF B group was low. There 
was no significant difference between the scores of the 
reversible and irreversible jaundiced groups. In the HGF 
A group, peripheral fibrosis areas and ductal prolifera-
tion was observed. Similarly, in the EGF A group, fibrosis 
expansion areas were observed in the portal area. In the 
IGF A group, portal inflammation and piecemeal necrosis 
were determined, as well as ductal proliferation. Ductal 
proliferation and portal area expansion were seen in the 
TGF B group. The HGF A and HGF B groups showed 
similar histological findings. In addition to the EGF A 
group, focal necrosis and parancimal necrosis areas were 
observed in the EGF B group. There were no histological 
differences between the IGF A and IGF B groups. Ductal 
proliferation and portal area fibrosis in the TGF B group 
were less than in the TGF A group (Figs. 3, 4).  
Discussion
Cholestasis is a common clinical problem associated with 
bile duct obstructed diseases such as choledocholithiasis, 
periampullary cancer, and hepatocellular carcinomas. 
EGF and HGF have beneficial effects on liver injury and 
hepatic regeneration (Holmes et al. 2007; Noguchi et al. 
1991; Berlanga et  al. 1998). HGF, a potent mitogen for 
hepatocytes, is increased in various liver diseases. HGF 
has beneficial effects on hepatic cholestatic fibrosis (Li 
et al. 2007; Xia et al. 2006). Recent evidence has indicated 
that the growth hormone is involved in liver regenera-
tion. In liver regeneration induced by partial hepatecto-
mized mice, liver-specific IGF type 1 receptor knockout 
caused a significant decrease in hepatocyte proliferation 
Fig. 1 Tissue MDA levels in all groups. EGF A groups MDA level was 
significantly high than EGF B group. IGF A group’s MDA level was 
significantly high than IGF B group. (p < 0.05)
Fig. 2 Liver tissue antioxidant assay levels. In all groups there was no 
significantly difference in antioxidant assay levels
Table 2 Pathological examination score, tissue oxygenase 
level and MDA level of the all groups
Groups Pathology score Tissue oxygenase level MDA level
Sham 1 ± 0.5 0.13 ± 0.06 5.42 ± 1.25
HGF A 4.50 ± 0.71 0.10 ± 0.04 16.70 ± 1.61
EGF A 3.90 ± 0.32 0.11 ± 0.03 18.36 ± 1.53
IGF A 5.00 ± 1.05 0.14 ± 0.07 18.19 ± 1.76
TGF A 3.80 ± 1.14 0.14 ± 0.03 15.62 ± 1.86
Control A 5.30 ± 0.82 0.16 ± 0.07 16.58 ± 1.07
HGF B 4.40 ± 0.52 0.12 ± 0.04 15.45 ± 1.64
EGF B 4.00 ± 0.94 0.13 ± 0.06 14.88 ± 2.26
IGF B 5.20 ± 0.63 0.11 ± 0.03 14.81 ± 3.25
TGF B 3.30 ± 0.82 0.15 ± 0.04 15.06 ± 2.09
Control B 4.60 ± 0.70 0.10 ± 0.03 15.73 ± 1.89
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in males (Desbois-Mouthon et  al. 2006). TGF-beta 1 
plays a role in the liver cell regeneration and atypical bile 
duct proliferation and in areas of rapidly progressing 
atypical bile duct proliferation (Takiya et al. 1995). Serum 
HGF levels decreased gradually after biliary drainage in 
patients who showed decreased serum bilirubin levels 
(Higaki et al. 1999).
Known growth factors play a role in liver injury and 
liver regeneration, as supported by experimental stud-
ies. However, the role of growth factors in posticteric 
liver damage and prolonged cholestasis is not certain. 
In clinical cases, determining whether a biliary drain-
age procedure before surgery is useful or not is also a 
matter of debate; there have not been enough studies 
Table 3 Classification of scores based on the microscopic findings of liver tissue
Score Findings
0 Proliferation in 10 % of portal areas
1 Proliferation in 10–50 % of portal area
2 Proliferation in more than 50 % of portal areas
3 At least 50 % of portal areas participated in an environmentally proliferation
4 With a significant expansion in the portal system; at least 50 % of portal areas participated in an environmentally proliferation
5 In addition to Score 4; bridging necrosis between portal areas; less than 20 %
6 In addition to Score 4; bridging necrosis between portal areas; more than 20 %
Fig. 3 Histopathological evaluation of the liver tissues of rats (Hematoxylin and Eosin, ×100). a In control A group ductal proliferation score was 
significantly increased. Central necrosis, piecemeal necrosis and focal necrosis areas defined. b In EGF-A group. Fibrosis expansion areas seen in 
portal area. c In TGF-A group. Ductal proliferation and portal area fibsosis. d In TGF-B group. Ductal proliferation and portal area expansion
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on this subject (Makino et  al. 2006). Patients are com-
monly referred to the hospital after jaundice develops. As 
a result, prolonged jaundice is not a rare clinical condi-
tion. In our study, we have tried to determine the role of 
the growth factors on liver damage in obstructive jaun-
diced rats. Well-known growth factors that affect liver 
generation and prophylactic effects on liver damage were 
included in our study: HGF, EGF, IGF-1, and TGF-ß1.
In the present study, we determined the effect of growth 
factors on liver damage during primary and established 
jaundice. Bile duct ligation continued for 5  days in irre-
versible jaundiced groups, as defined in the literature 
(Georgiev et al. 2008). Tests of liver function were studied 
as evidence of liver damage and to inform the degree of 
cholestasis. We observed that the liver function tests were 
higher in both the reversible and irreversible jaundiced 
control groups versus the sham group. Liver tissue MDA 
levels were significantly higher in the EGF A and IGF A 
groups (p  <  0.05). Histopathological scores were lower 
in the EGF A and TGF A groups, but, however, higher in 
the IGF A group. It has been reported that the apoptotic 
index and the inflammatory response of liver fall away in 
EGF- and HGF-treated rats (Thatch et al. 2008). EGF has 
beneficial effects on cholestatic liver injury caused by bile 
duct ligation. EGF treatment was more effective in the 
irreversible group compared with the reversible group. 
IGF-1 was used in experimental obstructive jaundice 
to determine the apoptosis and ductular proliferation of 
liver tissue. After the administration of IGF-I, hepatocyte 
apoptosis was significantly diminished (Kirkland et  al. 
2010). However, in both the reversible and irreversible 
jaundiced groups; the IGF-1 treatment was ineffective for 
hepatic damage and posticteric liver injury. However, it 
is likely that there was no specific correlation between all 
reversible and irreversible jaundiced groups. In our study, 
histopathological results of IGF treatment groups were 
higher than in the control groups (p  <  0.05). The Histo-
pathological score of TGF B groups was lower than in the 
HGF B and Control B groups. Considering all the groups 
compared, there was no significant difference between 
the reversible and irreversible groups according to histo-
pathological changes (p > 0.05).
Fig. 4 Histopathological evaluation of the liver tissues of rats (Masson’s Trichrome, ×100) a In control A group ductal proliferation score was sig-
nificantly increased. Central necrosis, piecemeal necrosis and focal necrosis areas defined. b In EGF-A group. Fibrosis expansion areas seen in portal 
area. c In TGF-A group. Ductal proliferation and portal area fibsosis. d In TGF-B group. Ductal proliferation and portal area expansion
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As is known in the literature, hepatocyte apopto-
sis increased and parancimal and hepatocyte necrosis 
decreased in the liver tissue of common bile ligated rats 
treated with HGF (Li et  al. 2007). According to all the 
parameters of our study, the HGF treatment was found 
to be effective in irreversible jaundiced rats, consistent 
with the literature. EGF and HGF modulated the hepatic 
inflammatory response and apoptotic index in this estab-
lished liver-injury model and may diminish liver damage 
in patients with liver injuries (Thatch et al. 2008). EGF is 
responsible for liver regeneration (Yokoyama et al. 2007; 
Lai et  al. 1992; Kiso et  al. 1995; Rasmussen et  al. 1992; 
Date et al. 2000). EGF treatment was effective in the irre-
versible jaundiced group versus the Control A group. The 
histopathological scores of the EGF A group was lower 
versus Control A group. After administration of IGF-1, 
the increased hepatocyte apoptosis and ductular prolif-
eration after CBD ligation were significantly diminished 
(Sheen-Chen et  al. 2006). The IGF-1 treatment was not 
effective in both treatment groups. Fibronectin produc-
tion of both normal and injured hepatocyte was affected 
by the TGF-ß1 treatment (Kloek et  al. 2008). TGF ß 1 
treatment results in the regeneration of hepatocyte and 
increases the extracellular matrix in liver tissue. In histo-
pathological studies, hepatocyte regeneration and ductal 
proliferation were detected; the scores of the TGF A and 
B groups were significantly lower than those of the con-
trol groups (p < 0.05). This finding is likely an early result 
of TGF Beta-1 treatment; later studies caused liver fibro-
sis. However, HGF treatment was effective in the HGF A 
group, but not in the HGF B group. Despite decreased 
levels of liver necrosis and biochemical assays, there was 
no significant difference between the HGF B group and 
the Control B group. A cholestatic rat is more susceptible 
to post ischemic liver injury and these injurious effects 
were significantly attenuated by biliary decompres-
sion. The antioxidant capacity of the liver was strongly 
decreased in cholestatic livers (Aldana et al. 1994). In the 
study of Aldana et al.; HGF mRNA was elevated follow-
ing obstruction and showed increased expression  1  day 
after decompression, peaking at 2 days after repair. As a 
result, HGF may play a role in cellular proliferation dur-
ing repair or may act as a compensatory growth factor 
during injury (Aldana et al. 1994).
Conclusion
Growth factors have beneficial effects for preventing 
liver damage while obstructing jaundice. Furthermore, 
growth factors may play an effective role during the reso-
lution of jaundice. We purpose that growth factors could 
protect the liver from cholestatic injury if the patient is 
diagnosed before sustained jaundice. In addition, liver 
damage will decrease after bile drainage. Before chronic 
cholestatic liver injury is fully realized, the maintenance 
of HGF and EGF levels prevents liver damage.
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